184 related articles for article (PubMed ID: 33337373)
1. Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease.
Minta K; Brinkmalm G; Portelius E; Johansson P; Svensson J; Kettunen P; Wallin A; Zetterberg H; Blennow K; Andreasson U
J Alzheimers Dis; 2021; 79(2):729-741. PubMed ID: 33337373
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease.
Minta K; Portelius E; Janelidze S; Hansson O; Zetterberg H; Blennow K; Andreasson U
J Alzheimers Dis; 2019; 69(4):1213-1220. PubMed ID: 31156172
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid brevican and neurocan fragment patterns in human traumatic brain injury.
Minta K; Brinkmalm G; Thelin EP; Al Nimer F; Piehl F; Tullberg M; Jeppsson A; Portelius E; Zetterberg H; Blennow K; Andreasson U
Clin Chim Acta; 2021 Jan; 512():74-83. PubMed ID: 33275942
[TBL] [Abstract][Full Text] [Related]
4. Extracellular Matrix Changes in Subcellular Brain Fractions and Cerebrospinal Fluid of Alzheimer's Disease Patients.
Höhn L; Hußler W; Richter A; Smalla KH; Birkl-Toeglhofer AM; Birkl C; Vielhaber S; Leber SL; Gundelfinger ED; Haybaeck J; Schreiber S; Seidenbecher CI
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982604
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cerebrospinal fluid phosphorylated tau
Kiđemet-Piskač S; Babić Leko M; Blažeković A; Langer Horvat L; Klepac N; Sonicki Z; Kolenc D; Hof PR; Boban M; Mimica N; Borovečki F; Šimić G
CNS Neurosci Ther; 2018 Aug; 24(8):734-740. PubMed ID: 29453935
[TBL] [Abstract][Full Text] [Related]
6. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia.
Olsson B; Hertze J; Ohlsson M; Nägga K; Höglund K; Basun H; Annas P; Lannfelt L; Andreasen N; Minthon L; Zetterberg H; Blennow K; Hansson O
J Alzheimers Dis; 2013; 34(3):673-9. PubMed ID: 23254629
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia.
Nägga K; Gottfries J; Blennow K; Marcusson J
Dement Geriatr Cogn Disord; 2002; 14(4):183-90. PubMed ID: 12411760
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia.
Blennow K; Davidsson P; Wallin A; Gottfries CG; Svennerholm L
Int Psychogeriatr; 1994; 6(1):13-22; discussion 59-60. PubMed ID: 8054491
[TBL] [Abstract][Full Text] [Related]
10. Flotillin is a Novel Diagnostic Blood Marker of Alzheimer's Disease.
Abdullah M; Kimura N; Akatsu H; Hashizume Y; Ferdous T; Tachita T; Iida S; Zou K; Matsubara E; Michikawa M
J Alzheimers Dis; 2019; 72(4):1165-1176. PubMed ID: 31683489
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.
Bjerke M; Zetterberg H; Edman Å; Blennow K; Wallin A; Andreasson U
J Alzheimers Dis; 2011; 27(3):665-76. PubMed ID: 21860087
[TBL] [Abstract][Full Text] [Related]
12. Role of inflammatory and hemostatic biomarkers in Alzheimer's and vascular dementia - A pilot study from a tertiary center in Northern India.
Vishnu VY; Modi M; Garg VK; Mohanty M; Goyal MK; Lal V; Mittal BR; Prabhakar S
Asian J Psychiatr; 2017 Oct; 29():59-62. PubMed ID: 29061429
[TBL] [Abstract][Full Text] [Related]
13. Brevican and Neurocan Cleavage Products in the Cerebrospinal Fluid - Differential Occurrence in ALS, Epilepsy and Small Vessel Disease.
Hußler W; Höhn L; Stolz C; Vielhaber S; Garz C; Schmitt FC; Gundelfinger ED; Schreiber S; Seidenbecher CI
Front Cell Neurosci; 2022; 16():838432. PubMed ID: 35480959
[TBL] [Abstract][Full Text] [Related]
14. Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus.
Minta K; Jeppsson A; Brinkmalm G; Portelius E; Zetterberg H; Blennow K; Tullberg M; Andreasson U
Fluids Barriers CNS; 2021 May; 18(1):23. PubMed ID: 33985551
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury.
Minta K; Cullen NC; Nimer FA; Thelin EP; Piehl F; Clarin M; Tullberg M; Jeppsson A; Portelius E; Zetterberg H; Blennow K; Andreasson U
Clin Chem Lab Med; 2019 Sep; 57(10):1565-1573. PubMed ID: 30980710
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease.
Janelidze S; Hertze J; Zetterberg H; Landqvist Waldö M; Santillo A; Blennow K; Hansson O
Ann Clin Transl Neurol; 2016 Jan; 3(1):12-20. PubMed ID: 26783546
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia.
de Jong D; Jansen RW; Kremer BP; Verbeek MM
J Gerontol A Biol Sci Med Sci; 2006 Jul; 61(7):755-8. PubMed ID: 16870640
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid τ protein in differential diagnosis of Alzheimer's disease and vascular dementia in Chinese population: a meta-analysis.
Liu B; Tang Y; Shen Y; Cen L; Han M
Am J Alzheimers Dis Other Demen; 2014 Mar; 29(2):116-22. PubMed ID: 24164930
[TBL] [Abstract][Full Text] [Related]
19. Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia.
Fredman P; Wallin A; Blennow K; Davidsson P; Gottfries CG; Svennerholm L
Acta Neurol Scand; 1992 Feb; 85(2):103-6. PubMed ID: 1574982
[TBL] [Abstract][Full Text] [Related]
20. Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach.
Begcevic I; Brinc D; Brown M; Martinez-Morillo E; Goldhardt O; Grimmer T; Magdolen V; Batruch I; Diamandis EP
J Proteomics; 2018 Jun; 182():12-20. PubMed ID: 29684683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
